Data from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Authors:
- Keiju AokageKAKeiju Aokage
- Shohei KoyamaSKShohei Koyama
- Shogo KumagaiSKShogo Kumagai
- Kotaro NomuraKNKotaro Nomura
- Yoshihisa ShimadaYSYoshihisa Shimada
- Kiyotaka YohKYKiyotaka Yoh
- Masashi WakabayashiMWMasashi Wakabayashi
- Miki FukutaniMFMiki Fukutani
- Hideki FuruyaHFHideki Furuya
- Tomohiro MiyoshiTMTomohiro Miyoshi
- Kenta TaneKTKenta Tane
- Joji SamejimaJSJoji Samejima
Open Access
- 16 December 2024
- other
- Published by American Association for Cancer Research (AACR)